Zimmer Biomet Holdings Inc. (ZBH) continues to make waves in the bio-tech market despite underperforming in comparison to some competitors. The company's promising return trends, recent dividend announcement, and solid growth in Q4 and Full-Year 2023, paint a positive financial picture. While insiders have sold some of their stake, Jump Financial LLC and Mitsubishi UFJ Asset Management Co. Ltd., others such as Private Advisor Group LLC and Massachusetts Financial Services Co. MA have increased their holdings. Zimmer Biomet continues to meet Q1 earnings and outperform profit estimates resulting from robust demand for knee and hip devices. While the recovery rate has slightly slowed down amid the pandemic, the company is nonetheless gaining from market recovery and global growth. Assessments predicting the company as potentially undervalued and a strong value stock for the Long-Term imply positive market perception. Although ZBH's three-year losses and occasional share underperformance have dented its growth, Q1 revenues and full-year 2023 EPS have beaten expectations.
Zimmer Biomet Holdings ZBH News Analytics from Tue, 01 Aug 2023 07:00:00 GMT to Sun, 19 May 2024 15:02:33 GMT -
Rating 2
- Innovation 3
- Information 8
- Rumor -3
